Pembrolizumab,Lenvatinib,Sunitinib,Everolimus
merck,pfizer,eisai
['caveat']
 one caveat for patients and clinicians/data-scientists reviewing qol data is that they are fraught with analytical/inferential challenges. would be extremely careful interpreting them. good discussion on best practices here: 
Physician-Scientist, Oncologist, PI #MsaouelLab @MDAndersonNews | Tweets=my views | #kidneycancer #RenalMedullaryCarcinoma #endRMC #rarecancers